The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid.

AIM The Japan EPA Lipid Intervention Study (JELIS) reported a 19% reduction of the risk for coronary artery disease after long-term use of pure eicosapentaenoic acid (EPA) in Japanese patients with hypercholesterolemia. The variation in plasma fatty acid composition influenced the risk of coronary events. The aim of this study was to examine in JELIS participants the possible correlation of changes in plasma fatty acids with those of serum lipids. METHODS The coefficient for the correlation between the absolute change in plasma fatty acid concentrations and the changes in serum lipids was calculated in 13,901 JELIS participants. RESULTS Low-density lipoprotein (LDL) cholesterol exhibited a positive correlation with docosahexaenoic acid (DHA; r=0.117 in control group, r=0.155 in EPA group) and linoleic acid (r=0.139 in control group, r=0.177 in EPA group), but the correlation coefficients with EPA (r=0.097 in control group, r=-0.032 in EPA group) were less than 0.1. We distributed the patients into 9 groups according to tertiles of the change in EPA and DHA. The average absolute decrease of LDL cholesterol and L/H ratio in each group was significantly smaller (p<0.001) in the DHA-high tertile, but not in any EPA tertile. CONCLUSION The changes in DHA, but not in EPA, showed a positive correlation with the changes in LDL-cholesterol.

[1]  A. Minihane,et al.  Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. , 2002, The British journal of nutrition.

[2]  S. Egert,et al.  Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. , 2009, The Journal of nutrition.

[3]  D. Mozaffarian,et al.  Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention , 2009, Circulation.

[4]  Y. Matsuzawa,et al.  Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia. , 1992, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[5]  H. Origasa,et al.  Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). , 2003, American heart journal.

[6]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[7]  G. Franceschini,et al.  Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. , 2000, Atherosclerosis.

[8]  C. Ballantyne,et al.  Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. , 1999, Atherosclerosis.

[9]  H. Nihei,et al.  Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[10]  T. A. Jacobson,et al.  Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. , 2008, The American journal of clinical nutrition.

[11]  T. A. Jacobson,et al.  Erratum: Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis (Current Atherosclerosis Reports (2011) 13 (474-483) DOI:10.1007/s11883-011-0210-3) , 2012 .

[12]  J. Luten,et al.  The effect of various intakes of omega 3 fatty acids on the blood lipid composition in healthy human subjects. , 1981, The American journal of clinical nutrition.

[13]  J. Dyerberg,et al.  Fatty acid composition of the plasma lipids in Greenland Eskimos. , 1975, The American journal of clinical nutrition.

[14]  T. Hamamoto,et al.  Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. , 1982, Journal of nutritional science and vitaminology.

[15]  Y. Matsuzawa,et al.  Relationships between plasma fatty acid composition and coronary artery disease. , 2011, Journal of atherosclerosis and thrombosis.

[16]  A. Zampelas Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. , 2010, Atherosclerosis.

[17]  J. Dyerberg,et al.  Plasma Lipid and Lipoprotein Pattern in Greenlandic West-Coast Eskimos , 2009 .

[18]  H. Ginsberg,et al.  Safety and Efficacy of Omacor in Severe Hypertriglyceridemia , 1997, Journal of cardiovascular risk.

[19]  W. Harris,et al.  The comparative reductions of the plasma lipids and lipoproteins by dietary polyunsaturated fats: salmon oil versus vegetable oils. , 1983, Metabolism: clinical and experimental.

[20]  P. Durrington,et al.  An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia , 2001, Heart.

[21]  N Kromann,et al.  Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. , 2009, Acta medica Scandinavica.

[22]  T. A. Jacobson,et al.  Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis , 2011, Current atherosclerosis reports.

[23]  E. Schaefer,et al.  Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. , 1997, Journal of the American College of Nutrition.